VRG101

VRG101 is an investigational **oral small-molecule PIKfyve inhibitor** developed by Verge Genomics as a host-targeted broad-spectrum antiviral. It inhibits phosphoinositide kinase FYVE-type zinc finger containing, a lipid kinase involved in endolysosomal maturation and viral entry, and has shown preclinical antiviral activity against **SARS-CoV-2** as well as other human coronaviruses including **OC43** and **229E**. In preclinical studies, VRG101 demonstrated potent in vitro antiviral effects and improved lung pathology in SARS-CoV-2-infected hamsters. The compound was originally identified through Verge Genomics' computational platform in connection with **amyotrophic lateral sclerosis**, where impaired PIKfyve machinery has been implicated, but its described therapeutic positioning has centered on prophylactic or preemptive treatment of coronavirus infection.